Business Wire

New Shared Mobility Concept, Luxoft HALO, Introduces a Revolutionary Digital, Consumer-Grade In-Vehicle Experience

Share

Luxoft, a DXC Technology Company (NYSE: DXC), today in collaboration with LG Electronics, Amazon and Mapbox unveiled Luxoft HALO, the company’s latest shared mobility concept featuring a revolutionary digital, consumer-grade in-vehicle experience. Luxoft HALO will be formally debuted at CES® 2020, Jan. 7-10, 2020, Las Vegas, NV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005099/en/

Luxoft HALO, featuring a revolutionary digital, consumer-grade in-vehicle experience. Image courtesy of Luxoft.

Luxoft HALO, featuring a revolutionary digital, consumer-grade in-vehicle experience. Image courtesy of Luxoft.

At home, consumers expect their digital experiences to be simple, convenient and accessible at any time across a range of devices. Increasingly, consumers also expect access to their favorite content and services, in the vehicle and on the go.

Luxoft HALO shared mobility concept demonstrates how all consumers’ mobility needs can be seamlessly integrated with their personal digital lifestyle.

”Together with our key partners, we can now deliver a complete, highly personalized and intelligent in-vehicle consumer-grade experience, powered by webOS Auto, the platform for shared and intelligent mobility,” said Vildan Hasanbegovic, director of partnerships and head of marketing at Luxoft Automotive. ”It’s an open platform that delivers, with exceptional quality, an existing ecosystem of intelligent services and dynamic content — from in-vehicle infotainment to connected video streaming services and more — that is increasingly becoming an essential part of consumers‘ personal digital lifestyles.”

Luxoft can already deploy webOS Auto to large-scale series production systems, including:

  • Rear Seat Entertainment (RSE) for traditional needs;
  • Rear Seat Entertainment (RSE) with ride-hailing mode;
  • Cabin display for ride-hailing systems; and
  • Center stack display for ride-hailing systems.

Partner Innovations Showcased in Luxoft HALO

LG Electronics and webOS Auto

webOS Auto is an open and ideal platform for shared and intelligent mobility. webOS Auto provides features, and functionality, and incorporates all essential components such as multimedia processing, multi-display control, connectivity, security, offering improved comfort and convenience to passengers.

Alexa Auto

Alexa already helps you simplify and organize your life at home – now you can take her with you on the go with Alexa Auto. Alexa can help you play music, get directions, place calls, listen to audiobooks, control your smart home, and more, with just your voice – so you can keep your hands on the wheel and eyes on the road. Alexa is already available in dozens of vehicles from leading automakers, and Amazon has released services like the Alexa Auto SDK that make it easy for automakers and suppliers to integrate Alexa directly into their infotainment system. To learn more, visit amazon.com/alexa-auto/.

Mapbox

Mapbox is a live location data platform powering maps and navigation experiences for mobile, web, gaming, and automotive. Mapbox maintains SDKs for developers building for webOS Auto, Android, iOS, Unity 3D, and web, and APIs for rendering maps and performing spatial functions. Every month, over 150,000 developers build with Mapbox. Over 45,000 mobile apps are powered by Mapbox SDKs. Applications and platforms built by developers using Mapbox reach more than 600 million monthly active users.

Luxoft at CES® 2020

Visit Luxoft at CES for a personal, hands-on experience of Luxoft HALO and to experience the future of shared and intelligent mobility; booth #6928, North Hall, Tech East, Las Vegas Convention and World Trade Center.

About Luxoft

Luxoft, a DXC Technology Company, (NYSE: DXC), is a digital strategy and software engineering firm providing bespoke technology solutions that drive business change for customers the world over. Luxoft uses technology to enable business transformation, enhance customer experiences, and boost operational efficiency through its strategy, consulting, and engineering services. Luxoft combines a unique blend of engineering excellence and deep industry expertise, specializing in automotive, financial services, travel and hospitality, healthcare, life sciences, media and telecommunications. For more information, please visit www.luxoft.com.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.

All information set out in the materials is provided in good faith but does not form part of or constitute an offer or contract. Statements, figures, plans, views and representations are for presentation purposes and indicative only. Luxoft has made reasonable efforts to include accurate information, wherever possible. However, Luxoft makes no warranties or representations, expressed or implied, as to the completeness of the information provided. Luxoft will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in these materials.

Contact information

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom